- 询价
- 慢病毒载体是将目的基因序列导入普通细胞与难转染细胞中的一种强有力手段。慢病毒通过感染细胞，将目的基因转导至靶细胞的基因组，使目的基因在活体及体外实验均能持续表达。为获得高滴度和稳定均一的慢病毒，慢病毒的包装、纯化和滴度测定都需要较长时间和足够的经验，而GeneCopoeia拥有专业的慢病毒包装团队，保证产品的高质量。
- 中国
- 2025年07月15日
16 年钻石会员
企业认证
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 询价记录
- 文献和实验
- 技术资料
- 提供商：
GeneCopoeia
- 服务名称：
Lentifect™慢病毒颗粒及定制包装服务
Lentifect™慢病毒
慢病毒载体是将目的基因序列导入普通细胞与难转染细胞中的一种强有力手段。慢病毒通过感染细胞，将目的基因转导至靶细胞的基因组，使目的基因在活体及体外实验均能持续表达。为获得高滴度和稳定均一的慢病毒，慢病毒的包装、纯化和滴度测定都需要较长时间和足够的经验，而GeneCopoeia拥有专业的慢病毒包装团队，保证产品的高质量。
Lentifect™ 纯化慢病毒既提供预制产品，也可根据客户需求进行定制。慢病毒生产经过标准的实验流程，
使用高质量质粒DNA提取试剂盒、EndoFectin 转染试剂及TiterBoost 慢病毒滴度增强试剂。高质量的试剂和GeneCopoeia的专业技能可保证高滴度的慢病毒出品。
Lentifect™ 慢病毒产品优势:
- 慢病毒可即时用于实验，节约时间与成本；
- 严格的质量控制，保证高品质与高滴度；
- 可有效转导目的基因至难转染细胞和动物模型。
Lentifect™慢病毒颗粒及定制包装服务
GeneCopoeia可为您提供已包装好的纯化或未纯化慢病毒颗粒，也可提供客户定制慢病毒包装服务。高质量的质粒DNA、慢病毒转染试剂、滴度增强剂及丰富的实验经验保证了病毒颗粒的高滴度。
预制慢病毒产品
纯化慢病毒产品包括以下几种，可立即用于实验：
- 阳性和阴性慢病毒对照：eGFP, eYFP, eCFP, mCherry, PLUM, Firefly luciferase, Renilla luciferase, Gaussia luciferase
- 慢病毒载体的ORF表达克隆：可从数百种低价的慢病毒载体ORF克隆中获得您的目的基因。
- CRISPR相关预制慢病毒：Cas9 nuclease，sgRNA for PD-1、PD-L1、GFP、HUWE and EMX1.
- 诱导IPSC重编程预制慢病毒： c-Myc, Klf4, Oct4, Sox2, Nanog, Lin28, CRE recombinase, FLP recombinase.
- 细胞永生化预制慢病毒：SV40 small T & large T antigen, SV40 large T antigen, hTERT, CDK4, HOX, c-Myc, Bmi1 and HPV-16 E6-E7.
- 外泌体标记预制慢病毒：CD9, CD81 and CD63.
- 其它常用预制慢病毒：HIV tat, Cell structure lentivirus, CRE recombinase and FLP recombinase.
纯化慢病毒滴度可达108 TU/ ml。Lentifect™慢病毒产品均经过严格的质量控制，插入序列均经过测序验证和qPCR滴度验证。H1299细胞的转导效率可通过检测eGFP或mCherry的表达量获得。
客户定制慢病毒包装服务
GeneCopoeia为您提供包括ORF cDNA, shRNA, miRNA前体和miRNA抑制剂在内的慢病毒包装服务。服务周期根据服务内容不同而有所差异，最短为20个工作日，病毒滴度可达107 copies/ ml~109 copies/ ml，最终产品规格为200 µl、400 µl 或1 ml。
- 15000个人源基因表达克隆、1200个miRNA前体表达克隆、1200个miRNA inhibitor表达克隆。
- 载体均经过优化设计，从而使得表达克隆在目的细胞中可高效表达。
- 选择已构建好的表达克隆进行病毒包装服务，最快20个工作日即可提供病毒颗粒。
GeneCopoeia eGFP慢病毒感染H1299细胞
图1. 于24孔板中，使用图示用量的eGFP纯化慢病毒(catalog number LP303)感染H1299细胞(ATCC)，添加5 µg/ml polybrene试剂。感染72小时后，使用荧光显微镜观察eGFP表达情况。
GeneCopoeia mCherry慢病毒感染H1299细胞
图2. 于24孔板中，使用图示用量的eGFP纯化慢病毒(catalog number LP151)感染H1299细胞(ATCC)，添加5 µg/ml polybrene试剂。感染72小时后，使用荧光显微镜观察mCherry表达情况。
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
- 作者
- 内容
- 询问日期
文献和实验该产品被引用文献
Jiye Liu, et al. 2024. Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma. Nat Commun. DOI: 10.1038/s41467-024-45561-z [CD38 lentivirus plasmid]
Nayoung Kim, et al. 2024. Cathepsin C regulates tumor progression via the Yes-associated protein signaling pathway in non-small cell lung cancer. Am J Cancer Res. [OMICSLINK Human CTSC Lentiviral ORF expression clone]
Yanan Gu, et al. 2024.CYLD regulates cell ferroptosis through Hippo/YAP signaling in prostate cancer progression. Cell Death Dis. DOI: 10.1038/s41419-024-06464-5 [OMICSLINK CYLD shRNA clone and scramble control; Lentifect Lentiviral particles overexpressing CYLD]
Wanlu Liu, et al. 2024.Decreased expression of TXNIP is associated with poor prognosis and immune infiltration in kidney renal clear cell carcinoma. Oncol Lett. DOI: 10.3892/ol.2024.14230 [OMICSLINK Human TXNIP Lentiviral ORF expression clone and control clone]
Jinbin Chen, et al. 2024.Circular RNA hsa_circ_0050386 suppresses non-small cell lung cancer progression via regulating the SRSF3/FN1 axis. J Transl Med. DOI: 10.1186/s12967-023-04812-1 [OMICSLINK hsa_circ_0050386 shRNA clone; Lenti-Pac HIV Expression Packaging Kit Cat. No.LT001]
Eunhye Jung, et al. 2024.TXNIP in liver sinusoidal endothelial cells ameliorates alcohol-associated liver disease via nitric oxide production. Int J Biol Sci. DOI: 10.7150/ijbs.90781 [OMICSLINK Human TXNIP Lentiviral ORF expression clone Cat. No.EX-M0226-Lv105; Empty control vector for pReceiver-Lv105 Cat. No.EX-NEG-Lv105]
Valeria Pecci, et al. 2024.Targeting of H19/cell adhesion molecules circuitry by GSK-J4 epidrug inhibits metastatic progression in prostate cancer. Cancer Cell Int. DOI: 10.1186/s12935-024-03231-6 [OMICSLINK Lentivetor H19 Expression Clone Cat. No.LPP-CS-GS1189L-Lv201-01-050; Lentifect lentiviral particles Cat. No.LP146-050]
Jingbo Sun, et al. 2024.CircTBC1D22A inhibits the progression of colorectal cancer through autophagy regulated via miR-1825/ATG14 axis. iScience. DOI: 10.1016/j.isci.2024.109168 [OMICSLINK Human ATG14 ORF expression clone; Lentifect Lentiviral particles expressing the double fluorescence reporter fusion to LC3B(mcherry-EGFP-LC3B)]
Amanda A. Shea, et al. 2024.Obesity modulates the cellular and molecular microenvironment in the peritoneal cavity: implication for ovarian cancer risk. Front Immunol. DOI: 10.3389/fimmu.2023.1323399 [firefly luciferase (FFL)-encoding lentiviral particles]
Natalie K. Horvat, et al. 2024.Clinically relevant orthotopic pancreatic cancer models for adoptive T cell transfer therapy. J Immunother Cancer. DOI: 10.1136/jitc-2023-008086 [Lentifect Purified Lentivirus particles Cat. No.LPP-HLUC-Lv105-025-C]
Ohman Kwon, et al. 2024.Chemically-defined and scalable culture system for intestinal stem cells derived from human intestinal organoids. Nat Commun. DOI: 10.1038/s41467-024-45103-7 [Lentifect Lentiviral particles expressing eGFP (EF1α-Gene X-IRES2-EGFP-IRES-Puro)]
Vivian Truong Jones, et al. 2024.Inhibition of autocrine HGF maturation overcomes cetuximab resistance in colorectal cancer. Cell Mol Life Sci. DOI: 10.1007/s00018-023-05071-5 [Lenti-Pac HIV Expression Packaging Kit Cat. No.LT001]
Kaihua Zhong, et al. 2024.BIRC6 Modulates the Protein Stability of Axin to Regulate the Growth; Stemness; and Resistance of Renal Cancer Cells via the β-Catenin Pathway. ACS Omega. DOI: 10.1021/acsomega.3c07265 [OMICSLINK BIRC6 Lentiviral ORF expression clone]
Wen Hu, et al. 2024.PPM1G promotes cell proliferation via modulating mutant GOF p53 protein expression in hepatocellular carcinoma. iScience. DOI: 10.1016/j.isci.2024.109116 [OMICSLINK PPM1G Lentiviral ORF expression clone and positive control Cat. No.EX-A1751-Lv201, EX-EGFP-Lv201; OMICSLINK PPM1G shRNA clone Cat. No. HSH013921-LVRU6GP]
Jin Su, et al. 2024.Lactate/GPR81 recruits regulatory T cells by modulating CX3CL1 to promote immune resistance in a highly glycolytic gastric cancer. Oncoimmunology. DOI: 10.1080/2162402X.2024.2320951 [Lentifect Lentiviral particles expressing shRNA targeting GPR81]
Fanghui Chen, et al. 2024.HSP90 inhibition suppresses tumor glycolytic flux to potentiate the therapeutic efficacy of radiotherapy for head and neck cancer. Sci Adv. DOI: 10.1126/sciadv.adk3663 [293Ta Lentiviral Packaging Cell Line]
Nayoung Kim, et al. 2024. Cathepsin C regulates tumor progression via the Yes-associated protein signaling pathway in non-small cell lung cancer. Am J Cancer Res. [OMICSLINK Human CTSC Lentiviral ORF expression clone]
Yanan Gu, et al. 2024.CYLD regulates cell ferroptosis through Hippo/YAP signaling in prostate cancer progression. Cell Death Dis. DOI: 10.1038/s41419-024-06464-5 [OMICSLINK CYLD shRNA clone and scramble control; Lentifect Lentiviral particles overexpressing CYLD]
Wanlu Liu, et al. 2024.Decreased expression of TXNIP is associated with poor prognosis and immune infiltration in kidney renal clear cell carcinoma. Oncol Lett. DOI: 10.3892/ol.2024.14230 [OMICSLINK Human TXNIP Lentiviral ORF expression clone and control clone]
Jinbin Chen, et al. 2024.Circular RNA hsa_circ_0050386 suppresses non-small cell lung cancer progression via regulating the SRSF3/FN1 axis. J Transl Med. DOI: 10.1186/s12967-023-04812-1 [OMICSLINK hsa_circ_0050386 shRNA clone; Lenti-Pac HIV Expression Packaging Kit Cat. No.LT001]
Eunhye Jung, et al. 2024.TXNIP in liver sinusoidal endothelial cells ameliorates alcohol-associated liver disease via nitric oxide production. Int J Biol Sci. DOI: 10.7150/ijbs.90781 [OMICSLINK Human TXNIP Lentiviral ORF expression clone Cat. No.EX-M0226-Lv105; Empty control vector for pReceiver-Lv105 Cat. No.EX-NEG-Lv105]
Valeria Pecci, et al. 2024.Targeting of H19/cell adhesion molecules circuitry by GSK-J4 epidrug inhibits metastatic progression in prostate cancer. Cancer Cell Int. DOI: 10.1186/s12935-024-03231-6 [OMICSLINK Lentivetor H19 Expression Clone Cat. No.LPP-CS-GS1189L-Lv201-01-050; Lentifect lentiviral particles Cat. No.LP146-050]
Jingbo Sun, et al. 2024.CircTBC1D22A inhibits the progression of colorectal cancer through autophagy regulated via miR-1825/ATG14 axis. iScience. DOI: 10.1016/j.isci.2024.109168 [OMICSLINK Human ATG14 ORF expression clone; Lentifect Lentiviral particles expressing the double fluorescence reporter fusion to LC3B(mcherry-EGFP-LC3B)]
Amanda A. Shea, et al. 2024.Obesity modulates the cellular and molecular microenvironment in the peritoneal cavity: implication for ovarian cancer risk. Front Immunol. DOI: 10.3389/fimmu.2023.1323399 [firefly luciferase (FFL)-encoding lentiviral particles]
Natalie K. Horvat, et al. 2024.Clinically relevant orthotopic pancreatic cancer models for adoptive T cell transfer therapy. J Immunother Cancer. DOI: 10.1136/jitc-2023-008086 [Lentifect Purified Lentivirus particles Cat. No.LPP-HLUC-Lv105-025-C]
Ohman Kwon, et al. 2024.Chemically-defined and scalable culture system for intestinal stem cells derived from human intestinal organoids. Nat Commun. DOI: 10.1038/s41467-024-45103-7 [Lentifect Lentiviral particles expressing eGFP (EF1α-Gene X-IRES2-EGFP-IRES-Puro)]
Vivian Truong Jones, et al. 2024.Inhibition of autocrine HGF maturation overcomes cetuximab resistance in colorectal cancer. Cell Mol Life Sci. DOI: 10.1007/s00018-023-05071-5 [Lenti-Pac HIV Expression Packaging Kit Cat. No.LT001]
Kaihua Zhong, et al. 2024.BIRC6 Modulates the Protein Stability of Axin to Regulate the Growth; Stemness; and Resistance of Renal Cancer Cells via the β-Catenin Pathway. ACS Omega. DOI: 10.1021/acsomega.3c07265 [OMICSLINK BIRC6 Lentiviral ORF expression clone]
Wen Hu, et al. 2024.PPM1G promotes cell proliferation via modulating mutant GOF p53 protein expression in hepatocellular carcinoma. iScience. DOI: 10.1016/j.isci.2024.109116 [OMICSLINK PPM1G Lentiviral ORF expression clone and positive control Cat. No.EX-A1751-Lv201, EX-EGFP-Lv201; OMICSLINK PPM1G shRNA clone Cat. No. HSH013921-LVRU6GP]
Jin Su, et al. 2024.Lactate/GPR81 recruits regulatory T cells by modulating CX3CL1 to promote immune resistance in a highly glycolytic gastric cancer. Oncoimmunology. DOI: 10.1080/2162402X.2024.2320951 [Lentifect Lentiviral particles expressing shRNA targeting GPR81]
Fanghui Chen, et al. 2024.HSP90 inhibition suppresses tumor glycolytic flux to potentiate the therapeutic efficacy of radiotherapy for head and neck cancer. Sci Adv. DOI: 10.1126/sciadv.adk3663 [293Ta Lentiviral Packaging Cell Line]
技术资料文献支持
Lentifect™慢病毒颗粒及定制包装服务
询价
